Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis (ZENITH AD-2)

4 september 2026 bijgewerkt door: Nektar Therapeutics

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo.

The estimated participant overall duration is approximately 15 months.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

510

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35203
        • Werving
        • Nektar Investigative Site
    • California
      • Oxnard, California, Verenigde Staten, 93030
        • Werving
        • Nektar Investigative Site
      • Palmdale, California, Verenigde Staten, 93551
        • Werving
        • Nektar Investigative Site
      • Sacramento, California, Verenigde Staten, 95815
        • Werving
        • Nektar Investigative Site
    • Florida
      • Tamarac, Florida, Verenigde Staten, 33321
        • Werving
        • Nektar Investigative Site
    • Georgia
      • Savannah, Georgia, Verenigde Staten, 31406
        • Werving
        • Nektar Investigative Site
    • Louisiana
      • Metairie, Louisiana, Verenigde Staten, 70006
        • Werving
        • Nektar Investigative Site
    • Missouri
      • Kirksville, Missouri, Verenigde Staten, 63501
        • Werving
        • Nektar Investigative Site
      • Lee's Summit, Missouri, Verenigde Staten, 64064
        • Werving
        • Nektar Investigative Site
    • Nevada
      • Las Vegas, Nevada, Verenigde Staten, 89144
        • Werving
        • Nektar Investigative Site
    • New Jersey
      • Robbinsville, New Jersey, Verenigde Staten, 08691
        • Werving
        • Nektar Investigative Site
    • New York
      • The Bronx, New York, Verenigde Staten, 10455
        • Werving
        • Nektar Investigative Site
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43213
        • Werving
        • Nektar Investigative Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline
  • Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms

    ≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit

  • Patients must meet the following AD severity criteria:
  • IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline
  • ≥ 10.0% of BSA involvement at Screening and Baseline
  • EASI ≥ 16.0 at Screening and Baseline
  • Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy
  • Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives

Exclusion Criteria:

  • Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy
  • Are currently experiencing or have a history of unstable course of AD
  • History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit.
  • Have a history of TCS use suggestive of a high risk for topical corticosteroid (TCS) withdrawal
  • Have received any of the following treatments at any time before Screening: aldesleukin; investigational IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD
  • Have a current or recent acute, active infection

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Blinded Induction Period: Rezpegaldesleukin every 2 weeks
Rezpegaldesleukin every 2 weeks during the induction period
Farmaceutische vorm: Injectieoplossing. Toedieningsweg: subcutaan
Andere namen:
  • NKTR-358
Placebo-vergelijker: Blinded Induction Period: Placebo
Placebo every 2 weeks during the induction period
Farmaceutische vorm: Injectieoplossing. Toedieningsweg: subcutaan
Experimenteel: Blinded Maintenance Period: Rezpegaldesleukin every 4 weeks
Rezpegaldesleukin every 4 weeks during the maintenance period
Farmaceutische vorm: Injectieoplossing. Toedieningsweg: subcutaan
Andere namen:
  • NKTR-358
Experimenteel: Blinded Maintenance Period: Rezpegaldesleukin every 12 weeks
Rezpegaldesleukin every 12 weeks during the maintenance period
Farmaceutische vorm: Injectieoplossing. Toedieningsweg: subcutaan
Andere namen:
  • NKTR-358
Placebo-vergelijker: Blinded Maintenance Period: Placebo
Placebo every 4 weeks during the maintenance period
Farmaceutische vorm: Injectieoplossing. Toedieningsweg: subcutaan
Experimenteel: Open-Label Escape
Rezpegaldesleukin at a frequency determined by the investigator during the open-label escape
Farmaceutische vorm: Injectieoplossing. Toedieningsweg: subcutaan
Andere namen:
  • NKTR-358

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
Tijdsspanne: Week 0 and Week 24
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
Week 0 and Week 24
Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24
Tijdsspanne: Week 0 and Week 24
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
Week 0 and Week 24
Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)
Tijdsspanne: Week 0 and Week 24
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
Week 0 and Week 24

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
US only: Number of participants with a ≥ 75% reduction in EASI score from baseline at Week 24 (EASI-75)
Tijdsspanne: Week 0 and Week 24
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
Week 0 and Week 24
Number of participants with a ≥ 90% reduction in EASI score from baseline at Week 24 (EASI-90)
Tijdsspanne: Week 0 and Week 24
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
Week 0 and Week 24
Number of participants at week 6 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
Tijdsspanne: Week 0 and Week 6
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
Week 0 and Week 6
Number of participants at week 24 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
Tijdsspanne: Week 0 and Week 24
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
Week 0 and Week 24
Number of participants at week 6 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
Tijdsspanne: Week 0 and Week 6
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
Week 0 and Week 6
Number of participants at week 24 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
Tijdsspanne: Week 0 and Week 24
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
Week 0 and Week 24
Number of participants at week 6 achieving a 1.25-point or greater improvement in Atopic Dermatitis Sleep Scale Question 1 (ADSS Q1) in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
Tijdsspanne: Week 0 and Week 6
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
Week 0 and Week 6
Number of participants at week 24 achieving a 1.25-point or greater improvement in ADSS Q1 in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
Tijdsspanne: Week 0 and Week 24
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
Week 0 and Week 24
Change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline at Week 24 in the subpopulation of patients with a 0.5-point or greater ACQ-5 at baseline
Tijdsspanne: Week 0 and Week 24
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
Week 0 and Week 24
Number of participants at week 24 achieving a 0.5-point or greater improvement in ACQ-5 in the subset of participants with a 0.5-point or greater ACQ-5 at baseline
Tijdsspanne: Week 0 and Week 24
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
Week 0 and Week 24
Change in Sino-Nasal Outcome Test (SNOT-22) score from baseline at Week 24 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
Tijdsspanne: Week 0 and Week 24
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
Week 0 and Week 24
Number of participants at Week 24 achieving a 8.9-point or greater reduction from baseline in SNOT-22 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
Tijdsspanne: Week 0 and Week 24
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
Week 0 and Week 24
Number of participants at week 24 achieving an Adapted Investigator's Global Assessment (aIGA) response of 0 or 1
Tijdsspanne: Week 0 and Week 24
The aIGA scale ranges from 0 to 1, with a lower score indicating improvement in atopic dermatitis.
Week 0 and Week 24
Number of participants with treatment emergent adverse events (TEAEs)
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment emergent serious adverse events
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment related serious adverse events
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment emergent adverse events of special interest
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with treatment related adverse events of special interest
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with TEAEs leading to treatment discontinuation
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with TEAEs leading to dose hold
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56
Number of participants with TEAEs leading to dose modifications
Tijdsspanne: Through participant study completion, approximately Week 56
Through participant study completion, approximately Week 56

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Study Director, Nektar Therapeutics

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

7 augustus 2026

Primaire voltooiing (Geschat)

1 juni 2028

Studie voltooiing (Geschat)

1 januari 2029

Studieregistratiedata

Eerst ingediend

14 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 juli 2026

Eerst geplaatst (Werkelijk)

17 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 september 2026

Laatste update ingediend die voldeed aan QC-criteria

4 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 25-358-10
  • 2025 (Subsidie/contract van de Amerikaanse NIH: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • 2025-525129-11-00 (Ctis)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren